Cell therapy for patients
OwnerDemao Yanginventor
Life of this patent
Estimating the term…
Abstract
Materials and methods of treating a patient with type 2 diabetes mellitus, metabolic syndrome, obesity, infertility, high blood pressure, hyperthyroidism, and hypothyroidism, hyperlipidaemia, osteoporosis, osteoarthritis, hypoadrenalism, polycystic ovary syndrome, or Parkinson's disease comprising administering a therapeutically effective amount of ex vivo cultured activated peripheral blood mononuclear cells (PBMCs) to the patient. The ex vivo cultured activated cells are activated and cultured in a presence of a cytokine and may be autologous or allogeneic relative to the patient.
Claims20
A method of treating a patient with type 2 diabetes mellitus comprising
- administering a therapeutically effective amount of ex vivo activated peripheral blood mononuclear cells (PBMCs) to a patient with type 2 diabetes mellitus, the ex vivo activated PBMCs being autologous to the patient and activated by culturing in the presence of a cytokine,
- wherein the cytokine comprises Interleukin-2 (IL-2), granulocyte-macrophage colony stimulating factor (GM-CSF) or a combination thereof, and
- wherein administering comprises administering 2-20 doses of the ex vivo activated PBMCs to the patient over a period of time ranging from 1-26 weeks wherein a dose of the ex vivo activated PBMCs ranges from 1×105 to 2×108 cells.
A method of treating a patient with type 2 diabetes mellitus comprising
- obtaining a blood sample from a patient with type 2 diabetes mellitus,
- separating peripheral blood mononuclear cells (PBMCs) from the blood sample,
- culturing the PBMCs in the presence of a cytokine to form ex vivo activated PBMCs, wherein the cytokine comprises Interleukin-2 (IL-2), granulocyte-macrophage colony stimulating factor (GM-CSF) or combinations thereof, and
- administering a therapeutically effective amount of the ex vivo activated PBMCs to the patient, wherein the administering comprises administering 2-20 doses of the ex vivo activated PBMCs to the patient over a period of time ranging from 1-26 weeks wherein a dose of the ex vivo activated PBMCs ranges from 1×105 to 2×108 cells.
Dependencies are inferred from the claim text.